



#### ABCD and Renal Association Clinical Guidelines for Diabetic Nephropathy-CKD. Management of Dyslipidaemia and Hypertension in Adults

Dr Peter Winocour Dr Indranil Dasgupta

## Rationale

- No national practical evidence based guidelines for holistic management of diabetic nephropathy and CKD through the spectrum in type 1 and type 2 diabetes
- Recognition that diabetes and renal physicians need to apply a mutually agreed set of principles which benefits from pooled expertise and experience

## Process

- Working party and writing group set up initially in 2013
- Formal writing group work programme from 2014-2106
- Use of RA Clinical Guidelines criteria for grading evidence based recommendations
- Pubmed , MEDLINE and Cochrane database were searched for relevant papers and all relevant national and international guidelines reviewed

## The team !



# Management of lipid abnormalities in adults with DM and nephropathy-CKD

- Lipid metabolism differs in type 1 V type 2 DM
- T1DM HDLC high unless severe insulin deficiency
- T2DM insulin resistance dyslipidaemic picture (raised Trigs and reduced HDLC).
- Progressive CKD reduces HDL, Progressive proteinuria increases LDL
- Compositional atherogenic abnormalities seen with renal dysfunction in both T1 and T2 DM

## Recommendations for statins in T1DM

- All aged 40+ with normal renal function unless new LADA in well controlled DM with high HDLC
- All aged > 30 with persistent raised ACR
- Progressive early CKD (eGFR fall > 5 ml/min/yr)
- All with CKD3 or worse
- Aged 18-30 with persistent albuminuria especially with other CVD risk factors

## **Recommendations for statins in T2DM**

- All patients with CKD1-2 with albuminuria irrespective of age
- All patients with CKD3 or worse regardless of age
- Continue statins if dialysis commenced
- Commence statins in those starting dialysis especially if younger patients
- Commence-continue statins after renal transplantation

## **Statin dosage**

- Atorvastatin 20 mg If simvastain used, never more than 40 mg (20 mg Simvastatin is maximum dose if on Calcium Antagonist)
- High intensity 40-80 mg Atorvastatin if target TC 4 or non HDL C 2.5 not attained (especially in higher CVD risk with HbA1c > 75, smoking, dyslipidaemia, HBP, PDR)
- High intensity in all with CVD

## **Statin intolerance**

- Submaximal dose , rechallenge , switch statin
- Ezetimibe add on
- PCSK9 Inhibitors no current data or indication
- No role for fibrates in advanced CKD 3B-5
- Fenofibrate alone or with statin only in DM CKD3A or earlier stages to reduce microvascular events in those with residual dyslipidaemia
- Fenofibrate monitor eGFR no role in combination with ezetimibe


## <u>Audit standards</u>

- Proportion of patients with T1 and T2 DM at separate CKD-DM stages on statins
- Proportion of patients in these categories achieving key non HDLC target of < 2.5 mmol/l</li>
- Use of non statin therapies (e.g ezetimibe and fenofibrate)

# **Areas for further research**

- Statins impact on renal function limited benefit short term on proteinuria , none on GFR
- Role of PCSK9 Inhibitors in DM DN-CKD with or without CVD


#### BP control in diabetes reduces complications



Mean BP <180/100 vs <150/85 mmHg

UK Prospective Diabetes Study (UKPDS) Group. BMJ 1998; 317: 703-713

#### ACEi decrease proteinuria and slow progression REIN Study




Adapted from GISEN Study Group. Lancet (1997) 349: 1857-1863

#### ACE-inhibitor control of blood pressure







Adapted from HC Gerstein, Lancet 2000; 355: 253-59

ABCD RA Guideline for management of hypertension in diabetic nephropathy-chronic kidney disease

- Management of hypertension in patients with type 1 diabetes (T1D) and nephropathy
- Management of hypertension in patients with type 2 diabetes (T2D) and early CKD (stages 1 and 2)
- Management of hypertension in patients with diabetes and CKD stages 3, 4 and 5ND
- Management of hypertension in patients with diabetes who are on dialysis (CKD 5D)

#### Recommendations – T1D

- In patients with T1D and normoalbuminuria, we recommend a threshold for BP therapy ≥ 140/80 mmHg (Grade 1B).
- In T1D and persistent micro- or macro-albuminuria, we recommend that ACEI therapy should be considered irrespective of BP, and that the target upright BP should be ≤130/80 mmHg. (Grade 1B).
- There is no current evidence to support a role for ACEI therapy for BP or renal protection in normotensive, normoalbuminuric patients with T1D (Grade 1C).
- There is no firm evidence to support a role of dual RAAS blockade in patients with T1D (Grade 1C).

#### Research recommendations – T1D

- Presence of microalbuminuria may not be the best predictor of progressive CKD. What is the role for other markers (e.g. KIM-1)?
- What is the role of dual blockade in T1D nephropathy?
- What is the role of aldosterone receptor blockers or direct renin inhibitors in patients with T1D and nephropathy?
- Is there a role for home or ABP monitoring in the diagnosis and management of hypertension in T1D, particularly in those with autonomic neuropathy?
- What is the role of RAAS-blocking agents in patients with T1D, progressive renal decline and normoalbuminuria?

#### Recommendations for T2D with early CKD

- In patients with T2D and hypertension, we recommend salt intake of <5 g/d NaCl (Grade 1C).</li>
- In patients T2D, CKD and ACR<3 mg/mmol, we recommend target BP of <140/90 mmHg (Grade 1D).</li>
- In patients with T2D, CKD and ACR >3 mg/mmol, we suggest a target BP of <130/80 mmHg (Grade 2D).</li>
- We recommend that ACEIs (or ARBs if ACEI not tolerated) should be used in patients with T2D and CKD who have ACR >3 mg/mmol (Grade 2D). No evidence for dual RAAS blockade.
- There is no evidence to support ACEI or ARB as first-line agent for T2D, normal renal function and normal UAE (Grade 1A).

#### Recommendation for DM CKD stages 3-5

- We recommend monitoring of BP, ACR and U&E 2 to 4 times per year, depending on the stage of CKD and patient's need (Grade 1B).
- We <u>recommend</u> initiation of antihypertensive agents in patients with DM CKD 3-5 and ACR of <30 mg/mmol when their BP is >140/90 mmHg and a target of ≤140/90 mmHg (Grade 1B).
- We <u>suggest</u> initiation of antihypertensive agents in patients with DM CKD 3-5 and an ACR >30 mg/mmol when their BP >130/80 mmHg, and a target BP ≤130/80 mmHg (Grade 2C).
- We recommend the use of an ACEI (or an ARB if ACEI is not tolerated) as the first choice BP lowering agent in patients with DM CKD 3-5 and micro and macro-albuminuria (Grade 1B).

#### Research recommendations DM CKD 3-5

- What is the effect of intensive BP lowering (≤130/80 mmHg) on renal and cardiac outcomes in patients with DM CKD 3-5?
- What is the impact of dual RAAS blockade on renal and cardiac outcomes in patients with diabetes, CKD and proteinuria?
- What is the impact of aldosterone blockade on renal and cardiac outcomes in patients with DM CKD?
- What is the effect of long-term use of novel potassium binders together with RAAS blockade on renal and cardiac outcomes in patients with DM CKD?

#### Recommendations for DM CKD 5D

- We recommend that ABP or HBP measurement should be used to monitor BP in patients with DM CKD 5D (Grade 1C).
- Where ABP or HBP are not feasible, we suggest using pre, intra and post-dialysis BP measurements for HD patients, and clinic BP for PD patients(Grade 2D).
- We recommend volume control as a first-line management to optimise BP control (Grade 1B).
- We suggest salt reduction to less than 5 g/day to optimise blood pressure control (Grade 2C).
- We suggest a target upright inter-dialytic BP of ≤140/90 for patients with DM CKD 5D. Individualisation of the BP target for older patients with multiple comorbidities, to reduce adverse effects of BP lowering (Grade 2D).

#### Research recommendation DM CKD 5D

- Which BP measurement should be used to reduce LVH and mortality: pre-dialysis, post-dialysis, home or ABP?
- What is the optimal BP target?
- Does treatment with ACEI, ARB, calcium channel blockers or beta-blockers to lower BP reduce CV morbidity and mortality?
- Does salt restriction (<5 g/d) in patients with diabetes who are on dialysis influence BP control or CV outcomes?
- Is there a role for diuretic therapy in patients with diabetes who are on dialysis and have residual renal function?

#### Conclusion - BP guideline

- BP control and RAAS blockade are important in patients with diabetes and CKD
- However, there is lack of high quality evidence
- Most of the recommendations are based on moderate to very low quality evidence or extrapolation from evidence in non-diabetes CKD
- Particularly true for patients with diabetes who are on dialysis
- Therefore, a number of research recommendations have been made
- Further research to inform future guidelines